> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Torrent Pharma Expands Losartan Recall
- URL: https://www.fdaweb.com/torrent-pharma-expands-losartan-recall-2/
- Published: 2019-01-23T12:00:00.000Z
- Updated: 2026-09-15T00:56:37.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5143203

Torrent Pharmaceuticals has expanded its recall from 10 lots of losartan potassium tablets to include six lots of losartan potassium and hydrochlorothiazide tablets due to the detection a suspected carcinogenic impurity, N-nitrosodiethylamine (NDEA) in an active pharmaceutical ingredient manufactured by Hetero Labs Limited. NDEA occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen the international Agency for Research on Cancer. According to an [updated recall notice](https://www.fda.gov/Safety/Recalls/ucm629693.htm?utm%5Fcampaign=Losartan%20Potassium%20Tablets%2C%20USP%20and%20Losartan%20Potassium%20and%20Hydrochlorothiazide%20Tablets%2C%20USP&utm%5Fmedium=email&utm%5Fsource=Eloqua), Torrent is only recalling lots that contain NDEA above the acceptable daily intake levels characterized by FDA. Losartan is used to treat hypertension, hypertensive patients with left ventricular hypertrophy and nephropathy in Type 2 diabetes patients.